Veille bibliographique COVID-19 et maladies du globule rouge

Partager sur :

L’équipe projet de la filière vous propose une veille bibliographique spécifique COVID-19 et maladies du globule rouge. Les articles proposés sont classés par maladie, puis par date de mise en ligne ou de publication.

Ces articles sont recensés à titre d’information et n’indiquent aucunement un cautionnement de leur contenu par la filière. La qualité et la pertinence de leur contenu et des conclusions restent à l’appréciation des lecteurs. 

Dernière modification : 9 juillet 2021.

Hémoglobinopathies – Pathologies associées du globule rouge

  • Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. Roy NB, Telfer P, Eleftheriou P, et al. Br J Haematol. [published online ahead of print, 2020 Apr 24]. doi: 10.1111/bjh.16687
  • Care of patients with hemoglobin disorders during the COVID-19 pandemic: an overview of recommendations. Taher AT, Bou-Fakhredin R, Kreidieh F, Motta I, De Franceschi L, Cappellini MD. Am J Hematol. [published online ahead of print, 2020 May 11]. doi: 10.1002/ajh.25857
  • Rare anaemias, sickle cell disease and COVID-19. Vives Corrons JL, De Sanctis V. Acta Biomed. 2020 May 11;91(2):216-217. doi: 10.23750/abm.v91i2.9532
  • Management of hemoglobin disorders during the COVID-19 pandemic. Chowdhury SF, Anwar S. Front Med (Lausanne). 2020 Jun 9;7:306. doi: 10.3389/fmed.2020.00306
  • Preliminary data on COVID-19 in patients with hemoglobinopathies: a multicentre ICET-A study. de Sanctis V, Canatan D, Vives Corrons JL, et al. Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020046. doi: 10.4084/MJHID.2020.046
  • A case of COVID-19 in a patient with asymptomatic hemoglobin D thalassemia and glucose-6-phosphate dehydrogenase deficiency. Sasi S, Yassin MA, Nair AP, Al Maslamani MS. Am J Case Rep. 2020 Jul 22;21:e925788. doi: 10.12659/AJCR.925788
  • Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. Telfer P, De la Fuente J, Sohal M, et al. Haematologica. [published online ahead of print, 2020 Sep 10]. doi: 10.3324/haematol.2020.259440
  • Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course. The Sardinian experience. Littera R, Campagna M, Deidda S, Angioni G, Cipri S, Melis M, et al. Front Immunol. 2020 Dec 4;11:605688. doi: 10.3389/fimmu.2020.605688
  • A Southeast Asian perspective on the COVID-19 pandemic: Hemoglobin E (HbE)-trait confers resistance against COVID-19. Papadopoulos KI, Sutheesophon W, Manipalviratn S, Aw TC. Med Sci Monit Basic Res. 2021 Jan 5;27:e929207. doi: 10.12659/MSMBR.929207
  • COVID‐19‐associated oxidative damage to red blood cells. Khakwani M, Horgan C, Ewing J. Br J Haematol. [published online ahead of print, 2021 Jan 11]. doi: 10.1111/bjh.17317
  • Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy. Motta I, Marcon A, Carrabba MD, et al. Ann Hematol. [published online ahead of print, 2021 Feb 2]. doi: 10.1007/s00277-021-04442-x
  • A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic. Yasara N, Premawardhena A, Mettananda S. Orphanet J Rare Dis. 2021 Mar 1;16(1):114. doi: 10.1186/s13023-021-01757-w
  • Mental well-being in patients with transfusion-dependent anemias and hemochromatosis during the SARS-CoV-2 pandemic. Piperno R, Bertazioli G, Giulia R, Mariani R, Piperno A. Mediterr J Hematol Infect Dis. 2021 Feb 26, 13(1): e2021024. doi: 10.4084/MJHID.2021.024
  • Incidence rate of COVID-19 infection in hemoglobinopathies: a systematic review and meta-analysis. Haghpanah S, Hosseini-Bensenjan M, Sayadi M, Karimi M. Hemoglobin. [published online ahead of print, 2021 May 24]. doi: 10.1080/03630269.2021.1927751

Déficit en glucose-6-phosphate déshydrogénase (déficit en G6PD)

  • G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? Kassi EN, Papavassiliou KA, Papavassiliou AG. J Cell Mol Med. [published online ahead of print, 2020 Apr 12]. doi: 10.1111/jcmm.15312
  • Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths? Aydemir D, Ulusu NN. Pathog Glob Health 2020 May;114(3):109-110. Epub 2020 Apr 14:1-2. doi: 10.1080/20477724.2020.1751388
  • G6PD deficiency in COVID-19 pandemic: “A ghost in the ghost”. Al-Abdi S, Al-Aamri M. Hematol Oncol Stem Cell Ther. [published online ahead of print, 2020 Apr 18]. doi: 10.1016/j.hemonc.2020.04.002
  • Acute hemolysis by hydroxychloroquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury. De Franceschi L, Costa E, Dima F, Morandia M, Olivieri O. Eur J Intern Med. [published online ahead of print, 2020 Apr 20]. doi: 10.1016/j.ejim.2020.04.020
  • COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency. Beauverd Y, Adam Y, Assouline B, Samii K. Eur J Haematol. [published online ahead of print, 2020 Apr 23]. doi: 10.1111/EJH.13432
  • The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Capoluongo ED, Amato F, Castaldo G. Clin Chem Lab Med. [published online ahead of print, 2020 Apr 24]. doi: 10.1515/cclm-2020-0442
  • G6PD deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine. Kuipers MT, van Zwieten R, Heijmans J, et al. Am J Hematol. [published online ahead of print, 2020 May 10]. doi: 10.1002/ajh.25862
  • Why G6PD deficiency should be screened before COVID-19 treatment with hydroxychloroquine? Oymak Y, Karapinar TH, Devrim İ. J Pediatr Hematol Oncol. [published online ahead of print, 2020 June 2]. doi: 10.1097/MPH.0000000000001864
  • A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Maillart E, Leemans S, Van Noten H, et al. Infect Dis (Lond). [published online ahead of print, 2020 June 4]. doi: 10.1080/23744235.2020.1774644
  • Doubtful precipitation of hemolysis by hydroxychloroquine in glucose‐6‐phosphate dehydrogenase deficient patient with COVID‐19 infection. Afra TP, Vasudevan Nampoothiri R, Razmi T M. Eur J Haematol. [published online ahead of print, 2020 June 5]. doi: 10.1111/EJH.13460
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency and COVID-19 infection. Vick DJ. Mayo Clin Proc. [published online ahead of print, 2020 June 6]. doi: 10.1016/j.mayocp.2020.05.035
  • Glucose 6 phosphate dehydrogenase deficiency: an actionable risk factor for patients with COVID-19? Jamerson B, Haryadi T, Bohannon A. Arch Med Res. [published online ahead of print, 2020 June 7]. doi: 10.1016/j.ejim.2020.04.020
  • Methemoglobinemia in patient with G6PD deficiency and SARS-CoV-2 infection. Palmer K, Dick J, French W, Floro L, Ford M. Emerg Infect Dis. 2020 Sep. [published online ahead of print, 2020 June 24]. doi: 10.3201/eid2609.202353
  • Linking hydroxychloroquine to hemolysis in a ‘suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection – a critical appraisal. Afra TP, Vasudevan Nampoothiri R, Razmi T M, Bishurul Hafi NA. Eur J Intern Med. [published online ahead of print, 2020 July 7]. doi: 10.1016/j.ejim.2020.07.001
  • Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine. Ibrahim H, Perl A, Smith D, et al. Clin Immunol. [published online ahead of print, 2020 July 22]. doi: 10.1016/j.clim.2020.108544
  • Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of acute hemeolytic anaemia (AHA). Dar SA, Wahid M, Haque S, Almalki SS, Akhter N. Eur Rev Med Pharmacol Sci. 2020;24(15):7923-7924. doi:10.26355/eurrev_202008_22473
  • Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out. De Franceschi L, Costa E, Dima F, Morandi M, Olivieri O. Eur J Intern Med. [published online ahead of print, 2020 Aug 13]. doi:10.1016/j.ejim.2020.08.015
  • Hydroxychloroquine in a G6PD-deficient patient with COVID-19 complicated by haemolytic anaemia: culprit or innocent bystander? Mastroianni F, Colombie V, Claes G, Gilles A, Vandergheynst F, Place S. Eur J Case Rep Intern Med. 2020 Aug 18;7(9):001875. doi:10.12890/2020_001875
  • COVID-19 & hydroxychloroquine side-effects: glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia. Chaney S, Basirat A, McDermott R, Keenan N, Moloney E. QJM. [published online ahead of print, 2020 Sep 16]. 2020;hcaa267. doi:10.1093/qjmed/hcaa267
  • Glucose-6-phosphate dehydrogenase deficiency and SARS- CoV-2 mortality: Is there a link and what should we do? Fazel Nabavi S, Habtemariam S, Sureda A, et al. Clin Biochem. [published online ahead of print, 2020 Sep 17]. doi: 10.1016/j.clinbiochem.2020.09.004
  • The potential link between inherited G6PD deficiency, oxidative stress, and vitamin D deficiency and the racial inequities in mortality associated with COVID-19. Jain SK, Parsanathan R, Levine SN, Bocchini JA, Holick MF, Vanchiere JA. Free Radic Biol Med. [published online ahead of print, 2020 Oct 7]. doi: 10.1016/j.freeradbiomed.2020.10.002
  • Centrality of G6PD in COVID-19: the biochemical rationale and clinical implications. Buinitskaya Y, Gurinovich R, Wlodaver CG, Kastsiuchenka S. Front Med (Lausanne). 2020 Oct 22;7:584112. doi: 10.3389/fmed.2020.584112
  • Hemolytic anemia in a glucose-6-phosphate dehydrogenase-deficient patient receiving hydroxychloroquine for COVID-19: a case report. Aguilar J, Averbukh Y. Perm J. 2020;24. doi: 10.7812/TPP/20.158
  • « Hemolysis, or not hemolysis, that is the question ». Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency. Sgherza N, Dalfino L, Palma A, et al.Mediterr J Hematol Infect Dis. 2020 Nov 1;12(1):e2020076. doi: 10.4084/MJHID.2020.076
  • Methemoglobinemia and hemolytic anemia after COVID-19 infection without identifiable eliciting drug: a case-report. Lopes DV, Lazar Neto F, Marques LC, Lima RBO, Brandao AAGS. IDCases. [published online ahead of print, 2020 Nov 19]. doi: 10.1016/j.idcr.2020.e01013
  • G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19). Yang HC, Ma TH, Tjong WY, Stern A, Chiu DT. Free Radic Res. [published online ahead of print, 2021 Jan 6]. doi: 10.1080/10715762.2020.1866757
  • G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg? Youssef JG, Zahiruddin F, Youssef G, et al. Ann Hematol. [published online ahead of print, 2021 Jan 13]. doi: 10.1007/s00277-021-04395-1
  • Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review. Onori ME, Ricciardi Tenore C, Urbani A, et al. Mol Biol Rep. [published online ahead of print, 2021 Feb 23]. 2021 Feb 23:1–6. doi: 10.1007/s11033-021-06234-y
  • Glucose-6-phosphate dehydrogenase deficiency-associated hemolytic anemia and methemoglobinemia in a patient treated with hydroxychloroquine in the era of COVID-19. Laslett N, Hibbs J, Hallett M, Ghaneie A, Zemba-Palko V. Cureus. 2021 May 25;13(5):e15232. doi: 10.7759/cureus.15232
  • Management of children with glucose-6-phosphate dehydrogenase deficiency presenting with acute haemolytic crisis during the SARs-COV-2 pandemic. Elalfy M, Adly A, Eltonbary K et al. Vox Sang. [published online ahead of print, 2021 June 8]. doi: 10.1111/vox.13123

Drépanocytose

  • COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. Am J Hematol. [published online ahead of print, 2020 Apr 3]. doi: 10.1002/ajh.25809
  • Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Am J Hematol. [published online ahead of print, 2020 Apr 8]. doi: 10.1002/ajh.25821
  • Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. De Luna G, Habibi A, Deux JF, et al. Am J Hematol. [published online ahead of print, 2020 Apr 13]. doi: 10.1002/ajh.25833
  • Initiating adjunct low dose-hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic. DeBaun MR. Blood [published online ahead of print, 2020 Apr 13]. doi: 10.1182/blood.2020005992
  • COVID‐19 infection in patients with sickle cell disease. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. Br J Haematol. [published online ahead of print, 2020 Apr 21]. doi: 10.1111/bjh.16734
  • Mitigating the effect of the COVID-19 pandemic on sickle cell disease services in African countries. Dexter D, Simons D, Kiyaga C, et al. Lancet Haematol. [published online ahead of print, 2020 Apr 23]. doi: 10.1016/S2352-3026(20)30122-8
  • Dramatic improvement after Tocilizumab of a severe COVID-19 in a child with sickle cell disease and acute chest syndrome. Odièvre MH, de Marcellus C, Ducou, et al. Am J Hematol. [published online ahead of print,  2020 May 1]. doi: 10.1002/ajh.25855
  • COVID-19 infection and sickle cell disease: a UK centre experience. McCloskey KA, Meenan J, Hall R, Tsitsikas DA. Br J Haematol. [published online ahead of print, 2020 May 5]. doi: 10.1111/bjh.16779
  • Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic. Nickel RS, Margulies S, Frazer B, Luban NLC, Webb J. Blood [published online ahead of print, 2020 May 13]. doi: 10.1182/blood.2020006582
  • Patients with sickle cell disease and suspected COVID‐19 in a pediatric ICU. Heilbronner C, Berteloot L, Tremolieres P, et al. Br J Haematol. [published online ahead of print, 2020 May 18]. doi: 10.1111/bjh.16802
  • Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. Sahu KK, Siddiqui AD, Cerny J. Br J Haematol. [published online ahead of print, 2020 May 23]. doi: 10.1111/bjh.16880
  • [Commentaire sur l’article DeBaun MR., Initiating adjunct low dose-hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic, mis en ligne le 13 avril et cité ci-dessus] COVID-19 and SCA: an old friend comes to the rescue. Novelli EM. Blood, 2020 May 28;135(22):1925-1926. doi: 10.1182/blood.2020006442
  • COVID-19 in patients with sickle cell disease – a case series from a UK Tertiary Hospital. Chakravorty S, Padmore-Payne G, Ike F, et al. Haematologica. [published online ahead of print, 2020 June 11]. doi: 10.3324/haematol.2020.254250
  • COVID-19 as a trigger of Acute Chest Syndrome in a pregnant woman with Sickle Cell Anemia. Justino CC, Campanharo FF, Augusto MN, Cezarino de Morais S, Figueiredo MS. Hematol Transfus Cell Ther. [published online ahead of print, 2020 June 18]. doi: 10.1016/j.htct.2020.06.003
  • Prognosis of patients with sickle cell disease and COVID-19: a French experience. Arlet JB, de Luna G, Khimoud D, et al. Lancet Haematol. [published online ahead of print, 2020 June 18]. doi: 10.1016/S2352-3026(20)30204-0
  • Sickle cell trait and the potential risk of severe coronavirus disease 2019 – A mini-review. Kehinde TA, Osundiji MA. Eur J Haematol. [published online ahead of print, 2020 June 26]. doi: 10.1111/ejh.13478
  • Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS‐CoV‐2 positivity. Quaresima M, Quaresima V, Naldini MM, et al. eJHaem. 2020:1-4. [published online ahead of print, 2020 July 4]. doi: 10.1002/jha2.53
  • Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease? Allison D, Campbell-Lee S, Crane J, et al. J Clin Apher. [published online ahead of print, 2020 July 6]. doi: 10.1002/jca.21809
  • Coronavirus disease among persons with sickle cell disease, United States, March 20–May 21, 2020. Panepinto JA, Brandow A, Mucalo L, et al. Emerg Infect Dis. 2020 Oct. [published online ahead of print, 2020 July 8]. doi: 10.3201/eid2610.202792
  • A Saudi family with sickle cell disease presented with acute crises and COVID‐19 infection. Al-Hebshi A, Zolaly M, Alshengeti A, et al. Pediatr Blood Cancer. 2020;e28547. [published online ahead of print, 2020 July 10]. doi: 10.1002/pbc.28547
  • Varying presentations and favourable outcomes of COVID-19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases. Appiah-Kubi A, Acharya S, Fein Levy C, et al. Br J Haematol. [published online ahead of print, 2020 July 11]. doi: 10.1111/bjh.17013
  • Vulnerability of sickle cell disease persons to the COVID-19 in sub-Saharan Africa. Tonen-Wolyec S, Marini Djang’eing’a R, Kambale-Kombi P, Tshilumba CK, Bélec L, Batina-Agasa S. Hematology. 2020 Dec;25(1):280-282. doi: 10.1080/16078454.2020.1790842
  • Impact of COVID-19 infection on 24 patients with sickle cell disease. One center urban experience, Detroit, MI, USA. Balanchivadze N, Kudirka AA, Askar S, et al. Hemoglobin. [published online ahead of print, 2020 July 28]. doi: 10.1080/03630269.2020.1797775
  • Implications of COVID-19 infections in sickle cell disease. John NA, John JE. Pan Afr Med J. 2020;36:81. Published 2020 Jun 9. doi:10.11604/pamj.2020.36.81.23776
  • Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes. Azerad MA, Bayoudh F, Weber T, et al. EJHaem. [published online ahead of print, 2020 Aug 4]. 2020;10.1002/jha2.74. doi:10.1002/jha2.74
  • SARS-CoV-2 infection in pediatric patient with hemoglobin SC disease. Dagalakis U, Hammershaimb E, McArthur MA, Macatangay RA. Pediatr Blood Cancer. [published online ahead of print, 2020 Aug 9]. 2020;e28430. doi:10.1002/pbc.28430
  • A pediatric patient with sickle cell disease presenting with severe anemia and splenic sequestration in the setting of COVID-19. Jacob S, Dworkin A, Romanos-Sirakis E. Pediatr Blood Cancer. [published online ahead of print, 2020 Aug 9]. 2020;e28511. doi:10.1002/pbc.28511
  • Sickle cell anemia and COVID-19: use of voxelotor to avoid transfusion. Ershler WB, Holbrook ME. Transfusion. [published online ahead of print, 2020 Aug 19]. 2020;10.1111/trf.16068. doi:10.1111/trf.16068
  • Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience. Ramachandran P, Perisetti A, Kathirvelu B, et al. eJHaem. [published online ahead of print, 2020 Aug 30]. 2020;1-7. doi: 10.1002/jha2.87
  • Challenges in the management of sickle cell disease during SARS-CoV-2 pandemic. Alsayegh F, Mousa SA. Clin Appl Thromb Hemost. [published online ahead of print, 2020 Sep 2]. 2020 Jan-Dec;26:1076029620955240. doi: 10.1177/1076029620955240
  • Acute chest syndrome in the setting of SARS‐COV‐2 infections—A case series at an urban medical center in the Bronx. Morrone KA, Strumph K, Liszewski MJ, et al. Pediatr Blood Cancer. [published online ahead of print, 2020 Sep 7]. 2020;e28579. doi: 10.1002/pbc.28579
  • Fatal viral infections in hemoglobin sickle cell C patients. Elenga N, Bansie R. Pediatr Blood Cancer. [published online ahead of print, 2020 Sep 8]. 2020;e28668. doi: 10.1002/pbc.28668
  • COVID-19 and sickle cell disease in Bahrain. AbdulRahman A, AlAli S, Yaghi O, et al. Int J Infect Dis. [published online ahead of print, 2020 Sep 24]. doi: 10.1016/j.ijid.2020.09.1433
  • Remodelling of specialist services enables safe reduction in hospital admissions of patients with sickle cell disease: Lessons from the COVID-19 pandemic. Tsitsikas DA, Lewis N, McCloskey K, et al. Clin Med (Lond). [published online ahead of print, 2020 Sep 29]. Vol 20, No 6 November 2020. doi: 10.7861/clinmed.2020-0474
  • COVID‐19 and the pulmonary complications of sickle cell disease. Sivalingam T, Inusa B, Doyle P, Oteng-Ntim E. eJHaem. [published online, 2020 Oct 8]. 2020;1-3. doi: 10.1002/jha2.105
  • COVID-19 and sickle cell disease. Menapace LA, Thein SL. Haematologica. [published online ahead of print, 2020 Oct 29]. doi: 10.3324/haematol.2020.255398
  • COVID-19 in Omani children with hemato-oncology diseases. Al Yazidi LS, Wali Y. Mediterr J Hematol Infect Dis. 2020 Nov 1;12(1):e2020074. doi: 10.4084/MJHID.2020.074
  • The role of red blood cell exchange in sickle cell disease in patient with COVID-19 infection and pulmonary infiltrates. Okar L, Aldeeb M, Yassin MA. Clin Case Rep. [published online ahead of print, 2020 Nov 16]. 2020;00:1-8. doi: 10.1002/ccr3.3526
  • Changes in care delivery for children with sickle cell anemia during the COVID-19 pandemic. Noisette ML, Phillips S, Schlenz AM, Mueller M, Kanter J. J Pediatr Hematol Oncol. [published online ahead of print, 2020 Nov 23]. doi: 10.1097/MPH.0000000000002008
  • Hemoglobinopathy and pediatrics in the time of covid-19. de Souza Vilela T, Braga JAP, Loggetto SR. Hematol Transfus Cell Ther. [published online ahead of print, 2020 Dec 2]. doi: 10.1016/j.htct.2020.11.002
  • Acute chest syndrome and COVID-19 in sickle cell disease pediatric patients. Mafra Elia G, Angel A, Regacini R, et al. Hematol Transfus Cell Ther. [published online ahead of print, 2020 Dec 19]. doi: 10.1016/j.htct.2020.11.005
  • Anxiety level and clinical course of patients with sickle cell disease during the COVID-19 outbreak. Tezol O, Unal S. Arch Pediatr. [published online ahead of print, 2020 Dec 23]. doi: 10.1016/j.arcped.2020.12.004
  • COVID-19 infection and acute pulmonary embolism in an adolescent female with sickle cell disease. Kasinathan S, Mohammad Ashraf H, Minkowitz S, Adeyinka A, Bailey-Correa K. Cureus. 2020 Dec 28;12(12):e12348. doi: 10.7759/cureus.12348
  • Clinical presentations and outcomes of COVID‐19 infection in sickle cell disease patients: Case series from Komfo Anokye teaching hospital, Ghana. Hardy YO, Amenuke DAY, Abukari Y, et al. Clin Case Rep. [published online ahead of print, 2020 Dec 31]. doi: 10.1002/ccr3.3719
  • COVID-19 pneumonia in a pediatric sickle cell patient requiring red blood cell exchange. Walker SC, Murphy ML, Hendricks H, Dulek DE, Volanakis EJ, Borinstein SC. Clin Case Rep. [published online ahead of print, 2021 Jan 12]. 2021;00:1-4. doi: 10.1002/ccr3.3774
  • Presentation, management, and outcomes of COVID‐19 in patients with sickle cell disease. Anusim N, Gupta R, Ahaneku H, et al. eJHaem. [published online ahead of print, 2021 Jan 12]. 2021;1-4. doi: 10.1002/jha2.162
  • Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Minniti CP, Zaidi AU, Nouraie M, et al. Blood Adv. 2021 Jan 12;5(1):207-215. doi: 10.1182/bloodadvances.2020003456
  • COVID-19 in patients with sickle cell disease: A single center experience from Ohio, United States. Sahu KK, George L, Jones N, Mangla A. J Med Virol. [published online ahead of print, 2021 Jan 21]. doi: 10.1002/jmv.26816
  • Acute hepatic encephalopathy and multiorgan failure in sickle cell disease and COVID-19. Martone GM, Nanjireddy PM, Craig RA, et al. Pediatr Blood Cancer. [published online ahead of print, 2021 Jan 23]. 2021 Jan 23:e28874. doi: 10.1002/pbc.28874
  • Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle cell disease adult patient: case report. Teulier M, Elabbadi A, Gerotziafas G, Lionnet F, Voiriot G, Fartoukh M. BMC Pulm Med. 2021 Jan 29;21(1):46. doi: 10.1186/s12890-021-01412-x
  • Simultaneous diagnosis of severe SARS-CoV-2 infection and sickle cell disease in two infants. Parodi E, Voi V, Vania B, et al. Blood Transfus. [published online ahead of print, 2021 Feb 3]. doi: 10.2450/2021.0430-20
  • Is sickle cell disease a risk factor for severe COVID-19 outcomes in hospitalized patients? A multicenter national retrospective cohort study. Abdulrahman A, Wael M, AlAmmadi F, et al. eJHaem. [published online ahead of print, 2021 Feb 10]. 2021;1-8. doi: 10.1002/jha2.170
  • Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease. Godby RC, Kornbrust A, Noubouossie D, et al. Int J Lab Hematol. [published online ahead of print, 2021 Feb 12]. doi: 10.1111/ijlh.13485
  • Severe hemolysis and vaso-occlusive crisis due to COVID-19 infection in a sickle cell disease patient improved after red blood cell exchange. Okar L, Rezek M, Gmeil A, Mulikandayhil Y, Yassin MA. Clin Case Rep. [published online ahead of print, 2021 Feb 22]. 2021;00:1-5. doi: 10.1002/ccr3.3960
  • Rapid development of seizures and PRES in a Covid-19 patient. Santos de Lima F, Klein S, El Ammar F, et al. Epilepsy Behav Rep. [published online ahead of print, 2021 Mar 4]. doi: 10.1016/j.ebr.2021.100436
  • Impact of the coronavirus 2019 (COVID-19) on vasooclusive crisis in patients with sickle cell anaemia. Alkindi S, Elsadek RA, Al-Madhani A, et al. Int J Infect Dis. 2021 Mar 16;S1201-9712(21)00262-9. doi: 10.1016/j.ijid.2021.03.044
  • SARS CoV-2 infection in a patient with sickle cell disease – Atypical presentation. Al-Naami AQ, Khan LA, Zaidan FI, et al. J Family Med Prim Care. 2021 Apr;10(4):1792-4. doi: 10.4103/jfmpc.jfmpc_2210_20
  • COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Singh A, Brandow AM, Panepinto JA. Blood Adv. 2021 Apr 13;5(7):1915-1921. doi: 10.1182/bloodadvances.2020003741
  • COVID-19 mortality in a pediatric patient with hemoglobin SC disease and alpha-thalassemia trait. Motelow JE, Kahn S, Wilson PT. Case Rep Crit Care. 2021 Apr 27;2021:6617362. doi: 10.1155/2021/6617362
  • COVID-19 presentation in patients with sickle cell disease: a case series. Chen-Goodspeed A, Idowu M. Am J Case Rep. 2021 May 4;22:e931758. doi: 10.12659/AJCR.931758
  • Low incidence of COVID-19 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon-1 activation? Brousse V, Holvoet L, Pescarmona R, et al. Haematologica. [published online ahead of print, 2021 May 13]. doi: 10.3324/haematol.2021.278573
  • Multisystem inflammatory syndrome in a pediatric patient with sickle cell disease and COVID-19: a case report. Español MG, Gardner RV, Alicea-Marrero MM, et al. J Pediatr Hematol Oncol. 2021 May 18. doi: 10.1097/MPH.0000000000002191
  • Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals. Boğa C, Asma S, Leblebisatan G, et al. Ann Hematol. [published online ahead of print, 2021 May 25]. doi: 10.1007/s00277-021-04549-1
  • Acute events in children with sickle cell disease in Italy during the COVID-19 pandemic: useful lessons learned. Munaretto V, Voi V, Palazzi G, et al. Br J Haematol. [published online ahead of print, 2021 May 25]. doi: 10.1111/bjh.17546
  • Sickle cell disease and COVID-19: Susceptibility and severity. Sayad B, Karimi M, Rahimi Z. Pediatr Blood Cancer. [published online ahead of print, 2021 June 1]. 2021:e29075. doi: 10.1002/pbc.29075
  • Educational technology on COVID-19 for families of children and adolescents with sickle cell disease. Oliveira PP, Gesteira ECR, Souza RL, et al. Rev BrasEnferm. 2021 Jun 11;74(suppl 1):e20201045. doi: 10.1590/0034-7167-2020-1045
  • Physicians’ opinions of COVID-19 ambulatory care constraints: a survey of sickle cell clinicians. Kenney MO, Becerra B, Beatty SA, Smith W. J Ambul Care Manage. [published online ahead of print, 2021 June 11]. doi: 10.1097/JAC.0000000000000386
  • Association of sickle cell trait with risk and mortality of COVID-19: results from the United Kingdom Biobank. Resurreccion WK, Hulsizer J, Shi Z, et al. Am J Trop Med Hyg. [published online ahead of print, 2021 June 15]. doi: 10.4269/ajtmh.20-1657
  • Low SARS-CoV-2 seroprevalence in a cohort of Brazilian sickle cell disease patients: Possible effects of emphasis on social isolation for a population initially considered to be at very high risk. Trafane LF, da Costa VA, da Silva Santos Duarte A, et al. eJHaem. [published online ahead of print, 2021 June 17]. doi: 10.1002/jha2.254
  • Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage. Uter S, An HH, Linder GE, et al. Blood Adv. 2021 Jun 22;5(12):2586-2592. doi: 10.1182/bloodadvances.2021004395
  • Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Mucalo L, Brandow AM, Dasgupta M, et al. Blood Adv. 2021 Jul 13;5(13):2717-2724. doi: 10.1182/bloodadvances.2021004288

Membranopathies (anomalies de la membrane du globule rouge)

  • COVID-19 and hereditary spherocytosis: A recipe for hemolysis. Severance TS, Rahim MQ, French J 2nd, et al. Pediatr Blood Cancer. 2020;e28548 [published online ahead of print, 2020 Jul 25]. doi: 10.1002/pbc.28548
  • Bilateral macular hemorrhage in a patient with COVID-19. D’Aloisio R, Nasillo V, Gironi M, Mastropasqua R. Am J Ophthalmol Case Rep. 2020 Dec;20:100958. doi: 10.1016/j.ajoc.2020.100958

Thalassémie

  • Challenging times for children with transfusion-dependent thalassemia amid the COVID-19 pandemic. Yadav U, Pal R. Indian Pediatr. [published online ahead of print, 2020 Apr 7]. doi: S097475591600155
  • SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. Motta I, Migone De Amicis M, Pinto VM, et al. Am J Hematol. [published online ahead of print, 2020 Apr 20]. doi: 10.1002/ajh.25840
  • Implications of SARSr-CoV 2 infection in thalassemias: do patients fall into the « high clinical risk » category? Karimi M, De Sanctis V. Acta Biomed. 2020 May 11;91(2):50-56. doi: 10.23750/abm.v91i2.9592
  • The medical concerns of patients with thalassemias at the time of COVID-19 outbreak: the personal experience and the international recommendations. Canatan D, De Sanctis V. Acta Biomed. 2020 May 11;91(2):218-221. doi: 10.23750/abm.v91i2.9533
  • Prevalence and mortality due to outbreak of novel coronavirus disease (COVID-19) in β-thalassemias: the nationwide Iranian experience. Karimi M, Haghpanah S, Azarkeivan A, et al. Br J Haematol. [published online ahead of print, 2020 June 2]. doi: 10.1111/bjh.16911
  • Thalassemic child presenting with anosmia due to COVID-19. Marhaeni W, Wijaya AB, Kusumaningtyas P, Mapianto RS. Indian J Pedriatr. [published online ahead of print, 2020 June 9]. doi: 10.1007/s12098-020-03370-4
  • COVID-19 in a Patient with β-Thalassemia Major and Severe Pulmonary Arterial Hypertension. Pinto VM, Derchi GE, Bacigalupo L, Pontali E, Forni GL. Hemoglobin. [published online ahead of print, 2020 June 18]. doi: 10.1080/03630269.2020.1779082
  • COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation. Farmakis D, Giakoumis A, Cannon L, Angastiniotis M, Eleftheriou A. Eur J Haematol. [published online ahead of print, 2020 June 23]. doi: 10.1111/ejh.13476
  • Thalassaemia prior and consequent to COVID-19 pandemic. The perspective of Thalassaemia International Federation (TIF). Eleftheriou A, Cannon L, Angastiniotis M. Thalassemia Reports. 2020 June;10:9138. doi: 10.4081/thal.2020.9138
  • Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects? Torti L, Maffei L, Sorrentino F, De Fabritiis P, Miceli R, Abruzzese E. Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020052. doi: 10.4084/MJHID.2020.052
  • COVID-19 infection in a child with thalassemia major after hematopoietic stem cell transplant. Sarbay H, Atay A, Malbora B. J Pediatr Hematol Oncol. [published online ahead of print, 2020 Jul 28].2020;10.1097/MPH.0000000000001895. doi:10.1097/MPH.0000000000001895
  • A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand. De Sanctis V, Canatan D, Vives Corrons JL, et al. Acta Biomed. 2020 Sep 7;91(3):e2020026. doi: 10.23750/abm.v91i3.10063
  • Prevalence and severity of coronavirus disease 2019 (COVID-19) in transfusion dependent and non-transfusion dependent β-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study. Karimi M, Haghpanah S, Zarei T, et al. Acta Biomed. 2020 Sep 7;91(3):e2020007. Published 2020 Sep 7. doi:10.23750/abm.v91i3.10155
  • COVID‐19 and thalassemia beta major in splenectomized patient: Clinical case progression and literature review. Okar L, Ali M, Parengal J, Yassin MA. Clin Case Rep. [published online ahead of print, 2020 Sep 12]. 2020;00:1–5. doi: 10.1002/ccr3.3345
  • The forgotten people with thalassemia in the time of COVID-19: South Asian perspective. Hossain MS, Raheem E, Siddiqee MH. Orphanet J Rare Dis. 2020 Sep 25;15(1):265. doi: 10.1186/s13023-020-01543-0
  • COVID‐19 pneumonia and pulmonary microembolism in a patient with B‐thalassemia major. Marziali M, Ribersani M, Losardo AA, et al. Clin Case Rep. [published online ahead of print, 2020 Sep 25]. 2020;00:1-4. doi : doi.org/10.1002/ccr3.3275
  • Thalassemia: with the « red » in the bag amid COVID-19 reflections. Pavate V. J Patient Exp. 2020 Aug;7(4):439-441. doi: 10.1177/2374373520951671
  • Vitamin and mineral supplementation for β-thalassemia during COVID-19 pandemic. d’Arqom A, G Putri M, Savitri Y, Rahul Alfaidin AM. Future Sci OA. 2020 Aug 18;6(9):FSO628. doi: 10.2144/fsoa-2020-0110
  • COVID-19 pandemic and thalassemia major patients: transfusion practice and treatment assessment. Oymak Y, Karapinar TH. J Pediatr Hematol Oncol. [published online ahead of print, 2020 Dec 2]. doi: 10.1097/MPH.0000000000002016
  • First report of COVID‐19 reinfection in a patient with beta-thalassemia major. Okar L, Ahmad R, Yassin MA. Clin Case Rep. [published online ahead of print, 2020 Dec 19]. 2020;00:1-5. doi: 10.1002/ccr3.3682
  • Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: a nationwide Iranian experience. Karimi M, Haghpanah S, Azarkeivan A, Matin S, Safaei A, De Sanctis V. Mediterr J Hematol Infect Dis. 2021 Jan 1;13(1): e2021008. doi: 10.4084/MJHID.2021.008
  • Coagulation abnormalities due to COVID-19 in a child with thalassemia. Marhaeni W, Wijaya AB, Khairiyadi, et al. Indian J Pediatr. [published online ahead of print, 2021 Jan 8]. doi: 10.1007/s12098-020-03600-9
  • An unusual cause of gastrointestinal perforation in an adolescent patient with beta-thalassemia on deferasirox and SARS-CoV-2 infection. Chauhan D, Kilic Y, Segal JP, Patel N, Koizia L. J Hematol. 2021 Apr;10(2):76-79. doi: 10.14740/jh815
  • SARS-CoV-2 infection in patients with β-thalassemia: Experience from Lebanon. Bou-Fakhredin R, Daadaa H, Koussa S, Abou Nasr T, Noun P, Taher AT. Am J Hematol. [published online ahead of print, 2021 Apr 29]. doi: 10.1002/ajh.26211
  • A case of ischemic colitis in a patient with non transfusion dependent thalassemia (NTDT) infected by SARS-COV-2. Ricchi P, Filosa A. Pediatr Hematol Oncol. [published online ahead of print, 2021 May 10]. doi: 10.1080/08880018.2021.1922558
  • Cold agglutinin associated with COVID-19 infection in a thalassemia patient with multiple alloantibodies: a case of cold hemagglutinin disease (CAD) with complex antibody detection. Ahmadnejad M, Mosleh M, Ferdowsi S, Mohammadi S, Eshghi P, Oodi A. Hematol Transfus Cell Ther. [published online ahead of print, 2021 May 26].doi: 10.1016/j.htct.2021.04.005
  • SARS-CoV-2 infection in patients with β-thalassemia: the French experience. Jean-Mignard E, De Luna G, Pascal L, Agouti I, Thuret I. Transfus Clin Biol. [published online ahead of print, 2021 July 1]. doi: 10.1016/j.tracli.2021.06.007